Aptose Biosciences, Inc.

Aptose Biosciences Inc. (“Aptose,” the “Company,” “we,” “us,” or “our”) is a science-driven clinical stage biotechnology company committed to the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s executive offices are located in San Diego, California, and our head office is located in Toronto, Canada.

Current securities

1. 15-12G filingJul 1, 2026
2. SC 13E3/A filingJul 1, 2026
3. Completion of Acquisition or Disposition of Assets · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsJul 1, 2026
4. Regulation FD DisclosureJul 1, 2026
5. Regulation FD DisclosureJun 15, 2026